- Conditions
- Alzheimer's Disease
- Interventions
- Avagacestat, Placebo
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 45 Years to 90 Years
- Enrollment
- 263 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 50
- States / cities
- Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 39 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 79
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- REM Sleep Behavior Disorder, Parkinson Disease, Lewy Body Dementia, Dementia With Lewy Bodies, Multiple System Atrophy, REM Sleep Parasomnias
- Interventions
- Not listed
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2028
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Redwood City, California • Atlanta, Georgia + 5 more
- Conditions
- Psychosis, Psychosis Nos/Other, Schizophrenia, Schizo Affective Disorder, Schizoaffective Disorder, Prodromal Schizophrenia, Schizophrenia Spectrum and Other Psychotic Disorders, Schizophreniform Disorders, Major Depression With Psychotic Features, Unspecified Psychosis, Bipolar Disorder
- Interventions
- Cognitive and Social Cognitive Training, Personalized Real-Time Intervention for Motivational Enhancement (PRIME) App, Early Psychosis Coordinated Specialty Care
- Device · Behavioral · Other
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 15 Years to 40 Years
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Alzheimer's Disease
- Interventions
- Gantenerumab, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 799 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2020
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • La Jolla, California • New Haven, Connecticut + 21 more
- Conditions
- Parkinson Disease, Prodromal Stage, Neurodegenerative Diseases, Basal Ganglia Diseases, Central Nervous System Diseases, Synucleinopathies, Nervous System Diseases, Cerebral Disorder, Brain Diseases, Parkinsonian Disorders, Genetic Predisposition
- Interventions
- Increase of physical activity volume and intensity with the use of a motivational smartphone application
- Behavioral
- Lead sponsor
- Radboud University Medical Center
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Alzheimer's Disease
- Interventions
- ALZT-OP1a, ALZT-OP1b, Placebo ALZT-OP1a, Placebo ALZT-OP1b
- Drug · Other
- Lead sponsor
- AZTherapies, Inc.
- Industry
- Eligibility
- 55 Years to 79 Years
- Enrollment
- 620 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 69
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 56 more
- Conditions
- Prodromal Schizophrenia, Prodromal Psychosis
- Interventions
- aripiprazole
- Drug
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 13 Years to 22 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 1
- States / cities
- Glen Oaks, New York
- Conditions
- Amyloid Plaque, Beta-Amyloid, DSAD, Prodromal Alzheimer's Disease, Alzheimer's Disease
- Interventions
- Placebo (Study Part 1a), ACI-24.060 at Dose A in Study Part 1a, ACI-24.060 at Dose B in Study Part 1a, ACI-24.060 at Dose C in Study Part 1a, ACI-24.060 with an additional adjuvant at Dose D in Study Part 1b, Placebo (Study Part 2), ACI-24.060 at Dose A in Study Part 2, ACI-24.060 at Dose B in Study Part 2, ACI-24.060 at Dose C in Study Part 2, Placebo (Study Part 1b), ACI-24.060 with an additional adjuvant at Dose E in Study Part 1b
- Biological
- Lead sponsor
- AC Immune SA
- Industry
- Eligibility
- 35 Years to 85 Years
- Enrollment
- 304 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Lady Lake, Florida • Orlando, Florida + 9 more
- Conditions
- Alzheimer Disease, Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer's Disease (Incl Subtypes), Mild Cognitive Impairment
- Interventions
- Not listed
- Lead sponsor
- Novoic Limited
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Santa Ana, California
- Conditions
- Prodromal Alzheimer's Disease, Preclinical Alzheimer's Disease, Healthy Aging, Cognitive Decline
- Interventions
- Active rTMS, Sham rTMS
- Device
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 40 Years to 99 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorder, Not Otherwise Specified, Prodromal Schizophrenia, Mood Disorder, Bipolar Disorder, Major Depressive Disorder, Depressive Disorder, Not Otherwise Specified, Mood Disorder, Not Otherwise Specified, Autism Spectrum Disorder
- Interventions
- Not listed
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 3 Years to 19 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- ARMS, APS, Prodromal Symptoms
- Interventions
- Cognitive Behavioral Therapy
- Behavioral
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 12 Years to 25 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2018
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Alzheimer's Disease
- Interventions
- Aducanumab (recombinant, fully human anti-Aβ IgG1 mAb), Placebo
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 197 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 32
- States / cities
- Tucson, Arizona • Laguna Hills, California • Lomita, California + 28 more
- Conditions
- REM Sleep Behavior Disorder, Parkinson Disease, Lewy Body Disease, Dementia With Lewy Bodies, Multiple System Atrophy, REM Sleep Parasomnias
- Interventions
- Not listed
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 9
- States / cities
- Sun City, Arizona • Los Angeles, California • Redwood City, California + 6 more
- Conditions
- Alzheimer's Disease
- Interventions
- [18F]GTP1
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2019
- U.S. locations
- 16
- States / cities
- New Haven, Connecticut • Stamford, Connecticut • Fort Myers, Florida + 13 more
- Conditions
- Prodromal Schizophrenia
- Interventions
- Step-Based Care Model
- Behavioral
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 12 Years to 25 Years
- Enrollment
- 100 participants
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Huntington Disease
- Interventions
- Not listed
- Lead sponsor
- CHDI Foundation, Inc.
- Other
- Eligibility
- 18 Years to 63 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 5
- States / cities
- San Diego, California • Englewood, Colorado • Boston, Massachusetts + 2 more
- Conditions
- Mild Cognitive Impairment, Prodromal Alzheimer's Disease
- Interventions
- AGB101, Placebo
- Drug
- Lead sponsor
- AgeneBio
- Industry
- Eligibility
- 55 Years to 85 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Alzheimer Disease (AD)
- Interventions
- [18F]GTP1, [18F]PI-2620, [18F]MK-6240
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Alzheimer Disease
- Interventions
- Gantenerumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 192 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 7
- States / cities
- Atlantis, Florida • Maitland, Florida • Ocala, Florida + 4 more
- Conditions
- Alzheimers Disease
- Interventions
- RO7126209, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 241 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 17
- States / cities
- Atlantis, Florida • Clermont, Florida • Lady Lake, Florida + 13 more
- Conditions
- Mild Cognitive Impairment, Mild Dementia, Parkinson Disease, Lewy Body Disease
- Interventions
- Placebo Oral Capsule, NYX-458
- Drug
- Lead sponsor
- Aptinyx
- Industry
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 26
- States / cities
- Scottsdale, Arizona • Fresno, California • Simi Valley, California + 20 more
- Conditions
- Parkinson Disease
- Interventions
- Not listed
- Lead sponsor
- Michael J. Fox Foundation for Parkinson's Research
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 3
- States / cities
- New Haven, Connecticut • Boston, Massachusetts • Philadelphia, Pennsylvania
- Conditions
- Alzheimer Disease
- Interventions
- Gantenerumab, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 1,053 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 33
- States / cities
- Tucson, Arizona • Irvine, California • Sacramento, California + 29 more